Aeterna Zentaris reports positive results from phase 2 perifosine, sorafenib combination therapy

The data has also reported positive clinical response activity in classical Hodgkin Lymphoma (HL) patients, who could be the target population for future studies.

Sponsored by the Fondazione IRCCS Istituto Nazionale Tumori, the trial included 40 patients with relapsed/refractory lymphomas who had failed second or subsequent-line salvage chemotherapy.

During the initial four week perifosine/sorafenib combination therapy, 36 patients have achieved less than partial response.

Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.